| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 | 1,563 | 1,571 | 1,759 | 1,854 | 1,862 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,285 | 1,230 | 1,311 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 | 425 | 398 | 474 | 625 | 551 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % | 24 % | 21 % | 24 % | 29 % | 27 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 | 97 | 100 | 101 | 139 | 118 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 216 | 184 | 262 | 367 | 317 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.23 |
Gland Pharma
Gland Pharma
2,922.30
-24.60
(-0.83%)
Market Cap
48,206.17 Cr
PE Ratio
43.08
Volume
3,89,004.00
Day High - Low
2,950.10 - 2,882.00
52W High-Low
3,042.00 - 1,573.60
There are 5 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
48,206.17 Cr
EPS
62.35
PE Ratio
43.08
PB Ratio
4.70
Book Value
627.88
EBITDA
1,945.90
Dividend Yield
0.68 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
9.92
Debt to Equity
0.03
Analyst Rating and Forecast
- By Refinitiv from15 analysts
Actual
Company News
View All News
Gland Pharma paid a combined ₹1.40 lakh penalty to NSE and BSE for a technical breach of SEBI LODR norms regarding the appointment of an independent director over 75. The company settled the full amount suo motu to ensure timely closure.
Gland Pharma to meet analysts and investors on Sept 115 days ago
Gland Pharma has scheduled a meeting with analysts and investors on September 11. The engagement reflects the company's ongoing investor relations activity.
Fosun Pharma likely to sell 5% stake in Gland Pharma10 days ago
Fosun Pharma is likely to offload a 5% equity stake in Gland Pharma via a block deal, according to reports by NDTV Profit.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,840.00 | #1 4,41,477.63 | 36.91 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 34.00 | |
9,322.00 | 2,47,469.81 | 85.36 | 11,067.00 | 13.95 | 2,568 | 65.50 | 63.65 | |
4,965.50 | 1,88,871.66 | 86.95 | 13,886.20 | 20.34 | 2,138 | 3.28 | 52.16 | |
1,119.10 | 1,12,607.65 | 24.28 | 27,657.90 | 17.64 | 5,026 | -34.90 | 45.64 | |
1,366.00 | 1,10,351.67 | 33.22 | 29,044.60 | 2.24 | 3,870 | -39.18 | 35.27 | |
1,969.00 | 1,06,297.76 | 95.94 | 6,867.80 | 22.01 | 890 | #1 123.93 | 68.28 | |
1,165.50 | 97,280.68 | 29.91 | 35,058.60 | 3.90 | 4,158 | -69.10 | 47.72 | |
1,679.80 | 96,651.98 | 25.88 | 34,145.20 | 5.56 | 3,503 | 25.21 | 57.04 | |
2,095.00 | 95,790.22 | #1 17.09 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 28.17 | |
2,280.00 | 94,163.08 | 44.87 | 14,636.40 | 14.85 | 1,938 | 29.13 | 37.57 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
15.73 %
Net Income Growth
47.07 %
Cash Flow Change
12.75 %
ROE
30.01 %
ROCE
20.10 %
EBITDA Margin (Avg.)
13.41 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 | 12,511 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 | 6,783 | 7,527 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 | 6,927 | 7,676 |
| Total Equity & Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 | 12,511 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 | 1,565 | 1,608 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 | 509 | 545 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 | 10,358 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,342 |
| Share Capital | 16 | 16 | 16 | 17 | 17 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 803 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 189 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 | -434 | -417 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.77 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % | 7.39 % | 7.91 % | 7.58 % | 7.30 % | 8.74 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % | 32.85 % | 32.64 % | 32.98 % | 33.35 % | 30.44 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % | 2.91 % | 2.57 % | 2.57 % | 2.53 % | 3.50 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % | 5.02 % | 5.06 % | 5.04 % | 4.98 % | 5.55 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 | 94,578 | 91,500 | 1,08,266 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 18 | 20 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 1.06 | 0.68 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 16 Aug 2024 |  Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
| 30 Aug 2024 |  Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 04 Nov 2024 |  Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 2,000.80 | 1,982.80 |
| 14 Aug 2025 | Dividend | ₹ 18.00 /share | 14 Aug 2025 | 1,484.15 | 1,950.30 |
| 28 Aug 2025 | Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 1,928.25 |
| 03 Nov 2025 | Quarterly Result Announcement | NA | 03 Nov 2025 | 1,917.60 | 1,928.90 |
| 28 Jan 2026 | Quarterly Result Announcement | NA | 28 Jan 2026 | 1,698.95 | 1,675.90 |
| 15 May 2026 | Quarterly Result Announcement | NA | 15 May 2026 | 1,794.40 | 1,898.20 |
| 10 Aug 2026 | Quarterly Result Announcement | NA | 10 Aug 2026 | 2,377.70 | 2,600.45 |
| 11 Aug 2026 | Dividend | ₹ 20.00 /share | 11 Aug 2026 | 1,898.20 | 2,667.30 |
| 25 Aug 2026 | Annual General Meeting | NA | 25 Aug 2026 | 1,898.20 | 2,801.60 |
Announcements
Announcement under Regulation 30 (LODR)-Acquisition
1 day ago
1 day agoBoard Meeting Outcome for Outcome Of Board Meeting1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS1 day ago
1 day agoGrant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 20251 day ago
1 day agoBoard Comments On Fines Levied By Exchanges1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoConclusion Of USFDA Inspection At Companys Facilities Situated At VisakhapatnamSep 01, 2026
Sep 01, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 31, 2026
Aug 31, 2026Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 26, 2026
Aug 26, 2026Shareholder Meeting / Postal Ballot-Outcome of AGMAug 25, 2026
Aug 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 23, 2026
Aug 23, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 17, 2026
Aug 17, 2026Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2026
Aug 14, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 11, 2026
Aug 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Investor PresentationAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 10, 2026
Aug 10, 2026Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30 2026Aug 10, 2026
Aug 10, 2026Unaudited Financial Results For The Quarter Ended June 30 2026Aug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 09, 2026
Aug 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2026
Aug 05, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2026
Aug 01, 2026Letter To ShareholdersJul 31, 2026
Jul 31, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2026
Jul 31, 2026Reg. 34 (1) Annual Report.Jul 31, 2026
Jul 31, 2026Notice Of 48Th AGMJul 31, 2026
Jul 31, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Issue of SecuritiesJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2026
Jul 29, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2026
Jul 28, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2026
Jul 24, 2026Board Meeting Intimation for Declaration Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026Jul 24, 2026
Jul 24, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateJul 20, 2026
Jul 20, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 20, 2026
Jul 20, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 20, 2026
Jul 20, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 16, 2026
Jul 16, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 14, 2026
Jul 14, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 13, 2026
Jul 13, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 22, 2026
Jun 22, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Jun 19, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 18, 2026
Jun 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 17, 2026
Jun 17, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2026
Jun 16, 2026Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 16, 2026
Jun 16, 2026Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 15, 2026
Jun 15, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.42
ATR(14)
Less Volatile 90.98
STOCH(9,6)
Neutral 70.27
STOCH RSI(14)
Neutral 36.04
MACD(12,26)
Bearish -7.89
ADX(14)
Strong Trend 38.60
UO(9)
Bearish 58.29
ROC(12)
Uptrend And Accelerating 0.66
WillR(14)
Neutral -45.02
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more
Listing Date
20 Nov, 2020(5 Years, 9 Months, 25 Days)
Website
Chairperson NameSRINIVAS SADU
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
